Palisade Bio Inc [NASDAQ: PALI] traded at a low on 2025-09-17, posting a -4.13 loss after which it closed the day’ session at $0.58.
The results of the trading session contributed to over 10836683 shares changing hands. Over the past one week, the price volatility of Palisade Bio Inc stands at 10.22% while the volatility over the past one month is 7.73%.
The market cap for PALI stock reached $5.26 million, with 9.12 million shares outstanding and 9.05 million shares in the current float. Compared to the average trading volume of 2.19M shares, PALI reached a trading volume of 10836683 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Palisade Bio Inc [PALI]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PALI shares is $8.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PALI stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 1.06, with the Price to Cash per share for the same quarter was set at 0.59.
How has PALI stock performed recently?
Palisade Bio Inc [PALI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.14. With this latest performance, PALI shares dropped by -27.90% in over the last four-week period, additionally sinking by -27.51% over the last 6 months – not to mention a drop of -65.00% in the past year of trading.
Palisade Bio Inc (PALI) Capital Structure & Debt Analysis
According to recent financial data for Palisade Bio Inc. ( PALI), the Return on Equity (ROE) stands at -188.48%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -121.25%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Palisade Bio Inc’s Return on Invested Capital (ROIC) is -452.10%, showcasing its effectiveness in deploying capital for earnings.
Palisade Bio Inc (PALI) Efficiency & Liquidity Metrics
Based on Palisade Bio Inc’s (PALI) latest financial statements, the Debt-to-Equity Ratio is 0.13%, indicating its reliance on debt financing relative to shareholder equity.
Palisade Bio Inc (PALI) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Palisade Bio Inc. (PALI) effectively leverages its workforce, generating an average of -$1481250.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.55% and a Quick Ratio of 1.55%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Palisade Bio Inc [PALI]
With the latest financial reports released by the company, Palisade Bio Inc posted -2.32/share EPS, while the average EPS was predicted by analysts to be reported at -3.36/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 1.04. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PALI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Palisade Bio Inc go to 51.67%.
Insider trade positions for Palisade Bio Inc [PALI]
There are presently around $6.18%, or 6.20%% of PALI stock, in the hands of institutional investors.
